RA
RVPH

Rosalind Advisors’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Rosalind Advisors’s Portfolio RVPH Stock Details RVPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-9,815
Closed -$1.01M – 38
2023
Q4 		$1.01M Buy
+9,815
New +$881K 0.83% 23

Other funds holding RVPH

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
ECM
EMC Capital Management Houston, Texas $253M AUM

Rosalind Advisors's RVPH Position: Q1 2024 in Review

Rosalind Advisors sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q1 2024, closing a stake of 9,815 shares — an estimated $1.01M sold.

Rosalind Advisors first reported a position in RVPH in Q4 2023 and held it in 1 quarter. The position peaked at $1.01M in Q4 2023. 28 funds tracked by Wall St. Rank hold RVPH as of Q1 2024.

  • Rosalind Advisors reported no remaining REVIVA PHARMA HLDGS INC position as of Q1 2024 after selling out during the quarter.
  • Rosalind Advisors sold 9,815 REVIVA PHARMA HLDGS INC shares in Q1 2024, an estimated $1.01M.
  • Rosalind Advisors first reported a position in REVIVA PHARMA HLDGS INC in Q4 2023 and held it in 1 quarter.
  • Rosalind Advisors's REVIVA PHARMA HLDGS INC position peaked at $1.01M in Q4 2023.
  • 28 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q1 2024.

Based on Rosalind Advisors's 13F filing for Q1 2024, filed 25 Apr 2024.